Subtype
Hypermobility spectrum disorder (HSD)
The residual category for symptomatic hypermobility falling short of hEDS criteria. Whether HSD and hEDS are meaningfully distinct is an open research question tracked by this index.
| Classification | Related hypermobility spectrum |
|---|---|
| Inheritance | unknown |
| Genes | none confirmed |
| Genetic status | unknown |
| Prevalence | More common than hEDS by definition of the residual category; true prevalence unresolved |
| Distinguishing | Symptomatic joint hypermobility not meeting the strict 2017 hEDS criteria; a clinical diagnosis |
| Reviewed | 2026-09-16 |
Related records
Records scoped to HSD or to all EDS types.
Subluxation, braces, taping, and joint-stabilization self-management
community signalcommunity signalAcross community venues the dominant practical corpus concerns joints that slip rather than dislocate — users trade taping, bracing, and stabilization techniques for joints that partially sublux without medical confirmation. The clinical literature acknowledges subluxation as a criterion-adjacent feature; the community knowledge layer is operational rather than diagnostic.
Community venues treat physical-therapy provider selection as a navigational problem — directories, word-of-mouth referrals, and filters for providers who do not prescribe harmful generic exercise. The "find an EDS-literate PT" pattern is a structural access problem, not a treatment dispute.
Community venues carry a mature caution corpus — local-anesthetic duration problems, post-operative flares, and medication-sensitivity reports that predate the clinical confirmation. This layer is now partly validated (the lidocaine arc) and partly still anecdotal (medication sensitivity reports).
Diagnosis navigation and specialist-finding strategies
community signalcommunity signalstrata convergeCommunity venues maintain informal routing — which specialists diagnose, which tests matter, how to prepare a diagnostic case. This is the community's response to the documented multi-year diagnostic delay, not a clinical pathway.
The "trifecta" — hEDS, POTS/dysautonomia, and MCAS co-clustering
community signalcommunity signalstrata convergePatient communities converged on the hEDS–POTS–MCAS triad years before it appeared in clinical reviews. Registry data now supports the clustering: in the Global Registry survey (n=505), POTS and mast cell activation syndrome were among the alternative diagnoses participants most endorsed as accurate. The triad is community-coined and increasingly clinically studied; the mechanism remains unexplained.
The 2017 classification moved EDS from a skin-and-joints frame to an explicitly multisystem one — systemic manifestations entered the hEDS criteria themselves, and companion papers covered GI, cardiovascular-autonomic, pain, and psychiatric comorbidity. This codified what patient communities had long reported.
The 2017 series and subsequent cohort work document gastrointestinal dysmotility (reflux, gastroparesis, constipation) and autonomic dysfunction (orthostatic intolerance, POTS) as leading comorbidity domains in hEDS/HSD. The German 2025 cohort shows musculoskeletal pain and joint instability as the dominant presenting manifestations.
The 2017 hEDS criteria require hypermobility, systemic manifestations, and exclusion
establishedfindingstrata convergehEDS diagnosis under the 2017 International Classification requires (1) generalized joint hypermobility by Beighton score, (2) two or more of systemic manifestations, positive family history, or musculoskeletal complications, and (3) exclusion of other connective-tissue disorders. Unlike every other subtype, hEDS has no molecular confirmation test.
Under the 2017 classification, definitive diagnosis of every subtype except hEDS relies on identifying a causative genetic variant. This asymmetry is the central classification problem: the most common type is the only one without a confirmatory test.
The 2017 framework (Castori et al.) separated symptomatic joint hypermobility into hEDS when the strict criteria are met and HSD when they are not. The boundary is contested — the criteria were designed for research homogeneity, not to declare HSD benign, and the hEDS/HSD criteria review study is ongoing.
Villefranche-era "EDS type III" cohorts (1997–2017) do not map cleanly onto 2017 hEDS — the new criteria are stricter and exclude cases now filed as HSD. This index tags every record with its criteria era; meta-claims mixing eras are read with caution.
The Hypermobile Ehlers-Danlos Genetic Evaluation study is the largest dedicated hEDS genetics effort, run under The Ehlers-Danlos Society's research program. First publications were expected late 2025 into 2026; this index tracks it as the pivotal watch item for the subtype.
Confirmed subtype genes cluster into collagen structure (COL5A1/A2, COL3A1, COL1A1/A2, COL12A1), collagen processing (ADAMTS2, PLOD1), proteoglycan and glycosaminoglycan pathways (B4GALT7, B3GALT6, CHST14, DSE), complement (C1R, C1S), and signaling (TNXB, SLC39A13, ZNF469, PRDM5, FKBP14). The 2017 classification groups subtypes by shared pathway for research purposes.
Beighton, Solomon, and Soskolne published the nine-point articular mobility score in an Annals of the Rheumatic Diseases population study — designed for epidemiology, later adopted as the clinical hypermobility measure still used in the 2017 hEDS criteria.
The 1988 Berlin nosology for heritable connective-tissue disorders expanded EDS into eleven numbered types — a proliferation that blurred clinical boundaries and set up the later consolidation.
Beighton et al. published the revised Villefranche nosology (1997, printed 1998) consolidating EDS to six major types — classical (I/II), hypermobility (III), vascular (IV), kyphoscoliosis (VI), arthrochalasia (VIIA/B), dermatosparaxis (VIIC) — aligning clinical types with the emerging molecular era.
Malfait et al. and the International EDS Consortium published the current classification: thirteen subtypes, molecular confirmation required for all except hEDS, a pathogenetic scheme grouping by pathway, and the companion framework separating hEDS from HSD. Management guidelines for comorbidities accompanied the criteria for the first time.
Clinical guidance positions individualized physical therapy — strengthening, proprioceptive work, pacing — as the primary management for hEDS/HSD. The honest limitation: the trial record is small and heterogeneous; the recommendation rests on expert consensus and cohort experience more than large trials.
Local anesthetic resistance — the index's reference convergence
establishedpracticestrata convergecautionPatients reported local-anesthetic failure for decades. Hakim and Grahame's 2005 survey found 58% of hypermobile patients reported inadequate anesthesia vs 21% of controls; a 2019 survey (n=988) found 88% vs 33%; in 2025 a randomized cross-over trial (n=135) confirmed shorter lidocaine duration in EDS patients. The arc — forum reports, structured survey, randomized confirmation — is the model this index exists to document.
Chopra et al.'s 2017 management paper remains the reference for EDS pain care — multimodal analgesia, physiotherapy, psychological support, and caution about long-term opioids. Evidence tiers here are low: mostly expert consensus and small series.
Tissue fragility, wound-healing complications, and — in vEDS — arterial rupture risk make surgery a deliberate decision. The 2017 orthopaedic guidance favors conservative management; the record is cautious rather than prohibitionist.
The diagnostic-odyssey literature documents medical gaslighting and post-traumatic stress in hEDS patients; management guidance includes psychological support. The 2025 BMJ phenomenological study urges trauma-informed care at the point of diagnosis.
The 2021 systematic review of the EDS diagnostic journey documents protracted time-to-diagnosis, serial misdiagnosis, and healthcare dismissal across patient populations. Delay is not an anecdote — it is a measured property of the system.
Diagnosis itself can be traumatic — the 2025 phenomenological record
establishedfindingstrata convergeThe 2025 BMJ phenomenological study (n=9, in-depth interviews) describes an "endless struggle" marked by uncertainty, dismissal, and medical gaslighting — and urges trauma-informed care at the diagnostic encounter itself. The psychiatric-label misdiagnosis burden is documented alongside it.
The 2025 German outpatient cohort (n=105, diagnosed 2021–2024) shows the real-world presentation profile: musculoskeletal pain, joint instability and subluxation as dominant features, alongside fatigue and the expected comorbidity load. A current-era complement to the criteria literature.
Fatigue is among the highest-burden symptoms in hEDS/HSD cohorts yet historically underweighted against joint and skin features. The 2017 multisystem criteria and subsequent cohort work restored it to the clinical picture.
The Ehlers-Danlos Society's DICE Global Registry is the central patient-powered research registry — the infrastructure behind the misdiagnosis survey and the recruitment rail for studies like HEDGE. Indexed as first-party registry infrastructure.
The ECHO program is the society's clinician-education and community-of-practice rail — how research and management knowledge reaches the providers patients actually see. Indexed as research-infrastructure, not a data source.
The federal trial registry is the canonical index of active EDS interventional and observational studies — the anesthetic-resistance RCT among them. The index's monitor tracks this portfolio for new registrations.
Orphanet (ORPHA:75531) and NIH GARD carry the reference-level disease records that anchor subtype nomenclature and prevalence estimates for rare-disease infrastructure. Indexed as reference rails rather than primary evidence.